Comparison of different sources of platelet-rich plasma as treatment option for infertility-causing endometrial pathologies

Miguel-Gómez, Lucía de; López-Martínez, Sara; Campo, Hannes; Francés-Herrero, Emilio; Faus, Amparo; Díaz, Ana; Pellicer, A.; Domı́nguez, Francisco; Cervelló, Irene

doi:10.1016/j.fertnstert.2020.07.053

Cited by 35 publications

(38 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…PRP-treated ovaries had significantly more pre-antral and antral follicles up to 30 days after treatment, suggesting that PRP may be a viable option for driving folliculogenesis in females with PCOS. In addition, platelets also release significant quantities of IL-15 when activated ( de Miguel-Gómez et al, 2020 ). Increased IL-15 concentrations in follicular fluid have been negatively correlated with pregnancy outcomes via IVF, indicating that this cytokine may be detrimental to follicle maturation ( Spanou et al , 2018 ).…”

Section: Prp: a Note Of Cautionmentioning

confidence: 99%

“…Even though there are other biological derivatives, such as human umbilical cord plasma, which may provide additional benefits in the sphere of ART ( de Miguel-Gómez et al, 2020 ), the appeal of PRP lies in its balance among therapeutic effect, cost effectiveness, ease of isolation and autologous nature. However, with the increased interest of ovarian PRP injection inconclusive efficacy and lack of understanding of mechanism of action, fundamental research into the effect of this therapy on the cellular level is required.…”

Section: Conclusion and Future Prospectsmentioning

confidence: 99%

See 1 more Smart Citation

Intraovarian injection of platelet-rich plasma in assisted reproduction: too much too soon?

2021

View full text Add to dashboard Cite

The prospect of ovarian rejuvenation offers the tantalising prospect of treating age-related declines in fertility or in pathological conditions such as premature ovarian failure. The concept of ovarian rejuvenation was invigorated by the indication of the existence of oogonial stem cells (OSCs), which have been shown experimentally to have the ability to differentiate into functional follicles and generate oocytes; however, their clinical potential remains unknown.  Furthermore, there is now growing interest in performing ovarian rejuvenation in situ.  One proposed approach involves injecting the ovary with platelet rich plasma (PRP). PRP is a component of blood that remains after the in vitro removal of red and white blood cells.  It contains blood platelets, tiny anucleate cells of the blood, which are responsible for forming a thrombus to prevent bleeding.  In addition, PRP contains an array of cytokines and growth factors, as well as a number of small molecules.  The utility of PRP has been investigated in a range of regenerative medicine approaches and has been shown to induce differentiation of a range of cell types, presumably through the action of cytokines.  A handful of case reports have described the use of PRP injections into the ovary in the human, and while these clinical data report promising results, knowledge on the mechanisms and safety of PRP injections into the ovary remain limited.  In this article, we summarise some of the physiological detail of platelets and PRP, before reviewing the existing emerging literature in this area. We then propose potential mechanisms by which PRP may be eliciting any effects before reflecting on some considerations for future studies in the area. Importantly, on the basis of our existing knowledge, we suggest that immediate use of PRP in clinical applications is perhaps premature and further fundamental and clinical research on the nature of ovarian insufficiency, as well as the mechanism by which PRP may act on the ovary, is needed to fully understand this promising development.

show abstract

Section: Prp: a Note Of Cautionmentioning

confidence: 99%

Section: Conclusion and Future Prospectsmentioning

confidence: 99%

Intraovarian injection of platelet-rich plasma in assisted reproduction: too much too soon?

2021

View full text Add to dashboard Cite

show abstract

“…ucPRP is derived from naive umbilical cord tissue, has a wide range of sources and more abundant growth factors than peripheral blood, and is a safe and effective substitute for patients with contraindications to autologous PRP [ 20 , 39 ]. A recent clinical study showed that ucPRP has a better effect than peripheral blood PRP for the treatment of endometrial injury infertility [ 40 ]. However, the beneficial effects of combined transplantation of HucMSCs and ucPRP in POF rats have not been discussed.…”

Section: Discussionmentioning

confidence: 99%

Activated Human Umbilical Cord Blood Platelet-Rich Plasma Enhances the Beneficial Effects of Human Umbilical Cord Mesenchymal Stem Cells in Chemotherapy-Induced POF Rats

Wang

Zhao

Zheng

et al. 2021

Stem Cells International

View full text Add to dashboard Cite

Saving the ovarian function of premature ovarian failure (POF) patients undergoing chemotherapy is an important problem in the field of reproductive medicine. At present, human umbilical cord mesenchymal stem cells (HucMSCs) have been used in the treatment of POF, but the effect is still not optimal. The purpose of this study was to determine whether human umbilical cord blood platelet-rich plasma (ucPRP) enhances the beneficial effects of HucMSCs in the treatment of POF. First, we observed the effects of changes in the biological activity of ucPRP on HucMSCs in vitro. Subsequently, we tracked the distribution and function of the HucMSCs in POF rats, and the rats’ estrus cycle and serum sex hormones, follicular development, ovarian angiogenesis, ovarian granulosa cell proliferation, and apoptosis were assessed. The results of the study showed that the addition of ucPRP in vitro accelerates proliferation and reduces apoptosis of the HucMSCs while upregulating the stemness gene of the HucMSCs. The combined transplantation of HucMSCs and ucPRP resulted in more stem cells being retained in the ovaries of POF rats, the estrus cycle of the POF rats being restored, the levels of serum E2, AMH, and FSH improving, and damaged follicles beginning to grow. Finally, we confirmed that the potential mechanism of the combination of HucMSCs and ucPRP to rescue the ovarian function of POF rats is to promote ovarian angiogenesis and to promote the proliferation and reduce the apoptosis of ovarian granulosa cells. The upregulation of AMH and FHSR expression and the downregulation of caspase-3 expression in granulosa cells are potential mechanisms for the recovery of ovarian function. Our research results suggest that the combined application of HucMSCs and ucPRP is a safe and efficient transplantation program for the treatment of POF, thus providing a reliable experimental basis for the clinical application of stem cell therapy in POF.

show abstract

“…Therefore, subsequent IUA management is considered necessary when IUA occurs. Thus far, there have been many publications addressing the topic of the management of IUA [ 23 , 24 , 26 , 27 , 28 , 29 , 30 , 35 , 40 , 43 , 57 , 58 , 59 , 62 , 64 , 131 , 132 , 133 , 134 , 135 , 136 , 138 , 139 , 140 , 141 , 142 , 155 , 164 , 165 , 166 , 167 , 168 ].…”

Section: Future Vision Of Iua Managementmentioning

confidence: 99%

Focus on the Primary Prevention of Intrauterine Adhesions: Current Concept and Vision

Lee

Liu

Chen

et al. 2021

IJMS

107

View full text Add to dashboard Cite

Intrauterine adhesion (IUA), and its severe form Asherman syndrome (Asherman’s syndrome), is a mysterious disease, often accompanied with severe clinical problems contributing to a significant impairment of reproductive function, such as menstrual disturbance (amenorrhea), infertility or recurrent pregnancy loss. Among these, its correlated infertility may be one of the most challenging problems. Although there are many etiologies for the development of IUA, uterine instrumentation is the main cause of IUA. Additionally, more complicated intrauterine surgeries can be performed by advanced technology, further increasing the risk of IUA. Strategies attempting to minimize the risk and reducing its severity are urgently needed. The current review will expand the level of our knowledge required to face the troublesome disease of IUA. It is separated into six sections, addressing the introduction of the normal cyclic endometrial repairing process and its abruption causing the formation of IUA; the etiology and prevalence of IUA; the diagnosis of IUA; the classification of IUA; the pathophysiology of IUA; and the primary prevention of IUA, including (1) delicate surgical techniques, such as the use of surgical instruments, energy systems, and pre-hysteroscopic management, (2) barrier methods, such as gels, intrauterine devices, intrauterine balloons, as well as membrane structures containing hyaluronate–carboxymethylcellulose or polyethylene oxide–sodium carboxymethylcellulose as anti-adhesive barrier.

show abstract

Comparison of different sources of platelet-rich plasma as treatment option for infertility-causing endometrial pathologies

Abstract: Objective. To study the effect of human plasma from different sources such as 2 umbilical cord blood and adult blood platelet-rich plasma (PRP) on the 3 regeneration of endometrial damage.

Cited by 35 publications

References 43 publications

Intraovarian injection of platelet-rich plasma in assisted reproduction: too much too soon?

Intraovarian injection of platelet-rich plasma in assisted reproduction: too much too soon?

Activated Human Umbilical Cord Blood Platelet-Rich Plasma Enhances the Beneficial Effects of Human Umbilical Cord Mesenchymal Stem Cells in Chemotherapy-Induced POF Rats

Focus on the Primary Prevention of Intrauterine Adhesions: Current Concept and Vision

Contact Info

Product

Resources

About